Fresenius Medical Care AG (FMS)
| Market Cap | 14.62B |
| Revenue (ttm) | 22.92B |
| Net Income (ttm) | 770.90M |
| Shares Out | 293.41M |
| EPS (ttm) | 2.62 |
| PE Ratio | 18.97 |
| Forward PE | 10.74 |
| Dividend | $0.57 (2.29%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 227,200 |
| Open | 24.70 |
| Previous Close | 24.20 |
| Day's Range | 24.63 - 24.95 |
| 52-Week Range | 18.42 - 30.46 |
| Beta | 0.86 |
| Analysts | Hold |
| Price Target | 30.00 (+20.65%) |
| Earnings Date | Aug 5, 2025 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for FMS stock is "Hold" and the 12-month stock price target is $30.0.
News
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical...
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger -...
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025
Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed t...
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalu...
$6.3 Trillion Outpatient Clinics Markets, 2021-2024 & 2025-2029 | Profiles of Leading Players - Johns Hopkins Medicine, Mayo Clinic, MD Anderson Cancer Center, Apollo Hospital, and Fresenius Medical
Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, a...
Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico
High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treat...
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG FMS on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture.
Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs
EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.
Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation
FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis...
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltrati...
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient out...
Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in th...
Fresenius Medical Care AG (FMS) Q1 2025 Earnings Conference Call Transcript
Fresenius Medical Care AG (FMS) Q1 2025 Earnings Conference Call Transcript
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million c...
Fresenius Medical Care tops market expectations in 1st quarter
World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 1...
Fresenius Medical Care's stock falls on Fresenius' stake sale
Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savin...
Fresenius Medical Care slightly beats market estimates in fourth quarter
Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery a...
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J...
Fresenius Medical Care: A 'Buy' Going Into 2025
Fresenius Medical Care is a leader in global kidney care, showing significant growth and an 18.5% increase since my last article. The company is attractively valued, trading at less than 18.5x P/E, wi...